BRCA突变携带者卵巢癌诊断后乳腺癌风险:预防性乳房切除术是否有必要?
该研究基于加拿大安大略省178例BRCA突变携带者队列估算卵巢癌年死亡率,并利用国际注册的509例BRCA突变携带者卵巢癌患者数据估算乳腺癌发病风险,通过模拟评估预防性乳房切除术和MRI筛查对全因死亡概率的降低效果。结果显示509例中20例(3.9%)在卵巢癌诊断后十年内发生乳腺癌,十年乳腺癌 actuarial 风险为7.8%。模拟表明,50岁诊断III/IV期卵巢癌的患者,MRI和乳房切除术分别使80岁前死亡概率降低不足1%和不足2%。作者认为,除无复发生存十年者和早期卵巢癌患者外,预防性乳房切除术和MRI筛查均不必要。
要点
- 509例BRCA突变携带者卵巢癌患者中,20例(3.9%)在诊断后十年内发生乳腺癌,十年 actuarial 风险为7.8%。
- 50岁诊断III/IV期卵巢癌者,MRI使80岁前死亡概率降低不足1%,乳房切除术降低不足2%。
- 作者认为,除无复发生存十年者和早期卵巢癌患者外,预防性乳房切除术和MRI筛查均不必要。
核心结论
- 对于无乳腺癌个人史的BRCA突变携带者卵巢癌患者,除无复发生存十年者和早期卵巢癌患者外,预防性乳房切除术和MRI筛查均不必要。
研究设计与样本
- 首先基于加拿大安大略省178例BRCA突变携带者队列估算卵巢癌患者年死亡率。
- 其次利用国际注册的509例BRCA突变携带者卵巢癌患者数据估算乳腺癌 actuarial 风险。
- 通过系列模拟评估乳房切除术和MRI筛查对全因死亡概率的降低效果,并使用Cox比例风险模型评估其对乳腺癌发病率和全因死亡率的影响。
主要发现
- 509例患者中20例(3.9%)在卵巢癌诊断后十年内发生乳腺癌。
- 在卵巢癌及其他原因死亡存活条件下,诊断后十年乳腺癌 actuarial 风险为7.8%。
- 模拟显示,50岁诊断III/IV期卵巢癌的BRCA突变携带者,MRI使80岁前死亡概率降低不足1%,乳房切除术降低不足2%。
- 对于卵巢癌后已存活10年者以及I或II期卵巢癌患者,MRI或乳房切除术带来的生存改善更大。
临床怎么用
- 作者认为,对于无乳腺癌个人史的BRCA突变携带者卵巢癌患者,除无复发生存十年者和早期卵巢癌患者外,预防性乳房切除术和MRI筛查均不必要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Preventive breast surgery and MRI screening are offered to unaffected BRCA mutation carriers. The clinical benefit of these two modalities has not been evaluated among mutation carriers with a history of ovarian cancer. Thus, we sought to determine whether or not BRCA mutation carriers with ovarian cancer would benefit from preventive mastectomy or from MRI screening. METHODS: First, the annual mortality rate for ovarian cancer patients was estimated for a cohort of 178 BRCA mutation carriers from Ontario, Canada. Next, the actuarial risk of developing breast cancer was estimated using an international registry of 509 BRCA mutation carriers with ovarian cancer. A series of simulations was conducted to evaluate the reduction in the probability of death (from all causes) associated with mastectomy and with MRI-based breast surveillance. Cox proportional hazards models were used to evaluate the impacts of mastectomy and MRI screening on breast cancer incidence as well as on all-cause mortality. RESULTS: Twenty (3.9%) of the 509 patients developed breast cancer within ten years following ovarian cancer diagnosis. The actuarial risk of developing breast cancer at ten years post-diagnosis, conditional on survival from ovarian cancer and other causes of mortality was 7.8%. Based on our simulation results, among all BRCA mutation-carrying patients diagnosed with stage III/IV ovarian cancer at age 50, the chance of dying before age 80 was reduced by less than 1% with MRI and by less than 2% with mastectomy. Greater improvements in survival with MRI or mastectomy were observed for women who had already survived 10years after ovarian cancer, and for women with stage I or II ovarian cancer. CONCLUSIONS: Among BRCA mutation-carrying ovarian cancer patients without a personal history of breast cancer, neither preventive mastectomy nor MRI screening is warranted, except for those who have survived ovarian cancer without recurrence for ten years and for those with early stage ovarian cancer.
引用
- McGee J, Giannakeas V, Karlan B, et al. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecol Oncol. 2017. PMID: 28314588. doi:10.1016/j.ygyno.2017.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。